COMMUNIQUÉS West-GlobeNewswire

Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
20/03/2026
SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world [...]
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
20/03/2026
MOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and commercializing [...]
CapsoVision Announces $14 Million Private Placement Financing
20/03/2026
Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results SARATOGA, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (the “Company”) (NASDAQ: CV), a commercial-stage medical [...]
Foundation Consumer Healthcare Sells Portion of Consumer Health Business
20/03/2026
Company Will Retain Flagship Brand, Plan B One-Step® PITTSBURGH, March 20, 2026 (GLOBE NEWSWIRE) -- Foundation Consumer Healthcare (FCH) announced today that it has entered into a definitive agreement to sell a portion [...]
Human Appeal to deliver food aid to thousands of displaced civilians as part of initial response in Lebanon
20/03/2026
Ongoing conflict in the Middle East region has left thousands of families displaced in Lebanon, with an increase in food poverty, poor water sanitation and illness observed MANCHESTER, United Kingdom, March 20, 2026 ( [...]
The Cost of Bleeding Revealed: Menstruation costs £20,359 a lifetime, sparking calls for Government action
20/03/2026
New consumer research reveals women and people with cycles spend an average of £20,359 on menstruating in their lifetime More than 1 in 3 (37%) of respondents struggle to afford period products 39% cut back on other [...]
On Match Day, ApolloMD Opens Applications for $5,000 Emergency Medicine Scholarship
20/03/2026
ATLANTA , March 20, 2026 (GLOBE NEWSWIRE) -- As medical students across the country learn where they will train during Match Day, ApolloMD is opening applications for its 2026 Emergency Medicine Scholarship . The annual [...]
Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
20/03/2026
Kensington, MD, USA and Munich/Martinsried, Germany, March 20, 2026 (GLOBE NEWSWIRE) -- Prodrug of oral amyloid beta aggregation modulator demonstrated improved absorption characteristics, leading to substantially [...]
Telix choisit le Cyclone® KIUBE d’IBA pour étendre ses capacités de production aux États‑Unis
20/03/2026
Louvain ‑ la ‑ Neuve, Belgique, le 20 mars 2026 — IBA (Ion Beam Applications S.A., EURONEXT) , leader mondial des technologies d’accélérateurs de particules et premier fournisseur mondial de solutions de production de [...]
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
20/03/2026
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, currently in a Phase 1/2 [...]
Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.
20/03/2026
Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, [...]
Pacific Health Care Organization, Inc. Reports its 2025 Year-End Financial Results
19/03/2026
Irvine, CA, March 19, 2026 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed Tuesday with the Securities and Exchange Commission (the “SEC”) its annual report on Form 10-K [...]
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
19/03/2026
-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction – -- [...]
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
20/03/2026
SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it [...]
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
20/03/2026
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 population In target Phase 2 population: 100% of patients became eligible to transplant [...]
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
19/03/2026
MISSISSAUGA, Ontario, March 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. Key [...]
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
19/03/2026
Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b long-term extension [...]
Cellectis publie ses résultats financiers du quatrième trimestre 2025 et de l’exercice 2025 et une mise à jour de ses activités
20/03/2026
Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2. Population cible de phase 2 : [...]
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
19/03/2026
Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profile [...]

Pages